Protective effects of carvedilol on systemic vascular damage induced by angiotensin II: Organ-specific effects independent of antihypertensive effects

Medical Science Monitor

Volumn 16, Issue 1, 2010, Pages

  Vailati, Maria Do Carmo Fernandez ^a   Rocha, Noeme Souza ^a   Matsubara, Luiz Shiguero ^a   Padovani, Carlos Roberto ^a   Schwartz, Denise Saretta ^b   Matsubara, Beatriz Bojikian ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arteries; Beta blockers; Hypertension; Necrosis

Indexed keywords

A 9525; ANGIOTENSIN II; CARVEDILOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE CUFF; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; DRUG EFFECT; HEART INJURY; HEART MUSCLE; HEART MUSCLE NECROSIS; HISTOLOGY; HYPERTENSION; KIDNEY INJURY; KIDNEY NECROSIS; LIVER NECROSIS; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; CARBAZOLES; HEART; HISTOCYTOCHEMISTRY; KIDNEY; LIVER; MALE; NECROSIS; PROPANOLAMINES; RATS; RATS, WISTAR; SYSTEMIC VASCULITIS;

EID: 75149167883     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Packer M, Coats AJ, Fowler MB et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001; 344: 1651-58
2. Krum H, Roecker EB, Mohacsi P et al: Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA, 2003; 289: 712-18
3. Poole-Wilson PA, Swedberg K, Cleland JG et al: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomized controlled trial. Lancet, 2003; 362: 7-13
4. Kveiborg B, Major-Petersen A, Christiansen B, Torp-Pedersen C: Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol or Metoprolol European Trial. Vasc Health Risk Manag, 2007; 3(1): 31-37
5. Campbell SE, Janicki JS, Weber KT: Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol, 1995; 27: 1545-60
6. Henegar JR, Brower GL, Kabour A, Janicki JS: Catecholamine response to chronic ANG II infusion and its role in myocyte and coronary vascular damage. Am J Physiol, 1995; 269: 1564-69
7. Henegar JR, Schwartz DD, Janicki JS: Ang II-related myocardial damage: role of cardiac sympathetic catecholamines and b-receptor regulation. Heart Circ Physiol, 1998; 275: H534-41
8. Bergstrom A, Andersson B, Edner M et al: Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail, 2004; 6: 453-61
9. Solal AC, Jondeau G, Beauvais F, Berdeaux A: Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail, 2004; 6: 463-66
10. Stroe AF, Gheorghiade M: Carvedilol: beta-blockade and beyond. Rev Cardiovasc Med, 2004; 5: S18-27
11. Cioffi G, Stefenelli C, Tarantini L, Opasich C: Chronic left ventricular failure in the community: prevalence, prognosis, and predictors of the complete clinical recovery with return of cardiac size and function to normal in patients undergoing optimal therapy. J Cardiac Failure, 2004; 10: 250-57
12. Bellenger NG, Rajappan K, Rahman SL et al: Effects of carvedilol on left ventricular remodeling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart, 2004; 90: 760-64
13. Kabour A, Henegar JR, Janicki S: Angiotensin II (AII)-induced myocyte necrosis: role of the AII receptor. J Cardiovasc Pharmacol, 1994; 23: 547-53
14. Kabour A, Henegar JR, Devineni VR, Janicki S: Prevention of angiotensin induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat. Cardiovasc Res, 1995, 29: 543-48
15. Tan LB, Jalil JE, Pick R et al: Cardiac myocyte necrosis induced by angiotensin II. Circ Res, 1991; 69: 1185-95
16. Brower GL, Henegar JR, Janicki JS: Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol, 1996; 271: H2071-78
17. Matsubara BB, Matsubara LS, Zornoff LAM et al: Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol, 1999; 93: 173-81
18. Fioretto JR, Querioz SS, Padovani CR et al: Matsubara BB. Ventricular remodeling and diastolic myocardial dysfunction in rats submitted to protein-calorie malnutrition. Am J Physiol, 2002; 282: H1327-33
19. Weber KT, Janicki JS, Reeves RC: Factors influencing left ventricular shortening in isolated canine heart. Am J Physiol, 1976; 230: 419-26
20. Hsu SM, Raine L, Fange RH: A comparative study of the peroxidase-antiperoxidase method and avidin biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clinic Pathol, 1981; 75: 734-41
21. Tarpley JE, Meschter CL, Tyler DE: Modified congo-red acidified toluidine blue strain: a new technique for simultaneous staining of eosinophils and mast cells in paraffin tissue section. J Histotechnol, 1984; 7: 141-42